Risk- and lab-guided treatment for young children with medulloblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child’s medulloblastoma must be newly diagnosed (suspected at first, then confirmed by the study’s central review).
- Your child must be under 60 months old when starting the study.
- Tumor tissue from the primary surgery must be available for study lab testing (molecular testing and pathology review).
- The trial treatment must start within 36 days after the definitive surgery (or the second surgery if needed to remove remaining tumor).
- Your child must have staging scans and a spinal fluid test (CSF) unless that procedure is medically unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This trial compares two standard treatment plans for young children with a specific type of medulloblastoma (a brain tumor). It looks at how each treatment affects thinking and learning over time, to see which one helps children do better in the long run.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial observes where medulloblastoma tumors first appear and how they grow during surgery. It helps doctors better understand these rare childhood and adult brain tumors.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.